自Ryman等开始将脂质体作为药物载体研究以来已取得很大进展。但药物脂质体用于临床的报道甚少,原因之一是脂质体对药物的包裹率较低,稳定性也差。较大的脂质体进入体内后主要被网状内皮系统所吞噬,不能较多地到达靶区,而小单层脂质体则在肝脾的 Much progress has been made since Ryman et al. Studied liposomes as drug carriers. However, there are few reports on liposomes for clinical use. One of the reasons is that the liposomes have a lower encapsulation rate and poor stability. Larger liposomes enter the body mainly by the reticuloendothelial system engulfed, can not reach the target more, and small single-layer liposomes in the liver and spleen